GlycoVaxyn's technology paves the way for synthesizing bioconjugate material to levels previously unattainable and in a more cost-effective manner.

04.05.10 GlycoVaxyn and a Harvard University affiliated hospital receive USD 3.4 million NIH grant 23.02.10 GlycoVaxyn's First Clinical Study with Bioconjugate Vaccine Initiated 06.10.09 GlycoVaxyn Appoints Renowned Vaccinologist Dr. Stanley A. Plotkin to Supervisory Board 05.03.09 GlycoVaxyn Announces its Series B Financing Round

GlycoVaxyn will be attending:

- the VacChina Vaccine Development Summit in Shanghai, China on September 15-16, 2010

GlycoVaxyn will be PRESENTING at:

- the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan on September 28, 2010

- the 10th Annual Biotech in Europe Investor Forum in Zurich, Switzerland on September 29-30, 2010

- the World Vaccine Congress taking place in Lyon, France on October 4-7, 2010